Khiron Life Sciences Corp. Applauds Election of Iván Duque as President of Colombia
Khiron Life Sciences Corp. Applauds Election of Iván Duque as President of Colombia |
[21-June-2018] |
President-Elect's platform promises significant economic measures to increase foreign investment and international trade TORONTO, June 21, 2018 /CNW/ - Khiron life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), a Canadian integrated medical cannabis company with its core operations in Colombia, wishes to congratulate President-Elect, Iván Duque of the Democratic Centre party, on winning the election on June 17, 2018 to become the next federal leader of Colombia. Mr. Duque will take over from incumbent President Juan Manuel Santos in August. Khiron views the election of Mr. Duque as a positive development for the nation and the people of Colombia, in general, as well as for the developing medical cannabis industry in Colombia, in particular. "Khiron applauds the election of Mr. Duque and is fully aligned with the new government's stated social and economic positions. In particular, we support the government elect's commitment to maintaining and improving upon a regulatory environment that enables and attracts foreign investment to create sustainable and secure job opportunities in emerging industries and to provide new health treatment alternatives for Colombians," said Alvaro Torres, CEO of Khiron. Core elements of Mr. Duque's agenda include:
"This landmark election result provides for the continuation of the important economic and social reforms that have helped Colombia gain standing and respect on global trade in recent years. We believe it will lead to the creation of jobs and sustainable growth in a stable economic environment for many years to come." Says Torres. About Khiron Life Sciences Corp. Khiron is a Canadian integrated medical cannabis company with its core operations in Colombia, and is fully licenced in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America. Further information on Khiron Life Sciences can be found at www.khiron.ca. Cautionary Note Forward-Looking Statements SOURCE Khiron Life Sciences Corp. | ||
Company Codes: TorontoVE:KHRN |
© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}